Clinical development of new drug-radiotherapy combinations

Nature Reviews Clinical Oncology

Volumn 13, Issue 10, 2016, Pages 627-642

  Sharma, Ricky A ^a   Plummer, Ruth ^b   Stock, Julie K ^c   Greenhalgh, Tessa A ^d   Ataman, Ozlem ^e   Kelly, Stephen ^f   Clay, Robert ^g   Adams, Richard A ^h   Baird, Richard D ⁱ   Billingham, Lucinda ^j   Brown, Sarah R ^k   Buckland, Sean ^f   Bulbeck, Helen ^l   Chalmers, Anthony J ^m   Clack, Glen ⁿ   Cranston, Aaron N ^o   Damstrup, Lars ^p   Ferraldeschi, Roberta ^q   Forster, Martin D ^a   Golec, Julian ^r   Hagan, Russell M ^s   Hall, Emma ^t   Hanauske, Axel R ^u   Harrington, Kevin J ^t   Haswell, Tom ^l   Hawkins, Maria A ^d   Illidge, Tim ^v   Jones, Hazel ^c   Kennedy, Andrew S ^w   Mcdonald, Fiona ^t   Melcher, Thorsten ^x   O'Connor, James P B ^v   Pollard, John R ^r   Saunders, Mark P ^v   Sebag Montefiore, David ^k   Smitt, Melanie ^y   Staffurth, John ^h   Stratford, Ian J ^v   Wedge, Stephen R ^b   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e EISAI CO LTD   (Japan)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^g SYNEOS HEALTH   (United States)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^k UNIVERSITY OF LEEDS   (United Kingdom)

^l Portland House   (United Kingdom)

^m UNIVERSITY OF GLASGOW   (United Kingdom)

ⁿ ASTRAZENECA   (United Kingdom)

^o Babraham Research Campus Babraham   (United Kingdom)

^p MERCK KGAA   (Germany)

^q ASTEX PHARMACEUTICALS   (United Kingdom)

^r VERTEX PHARMACEUTICALS   (United States)

^s BIOCOMPATIBLES UK LTD   (United Kingdom)

^t INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^u ELI LILLY AND COMPANY   (United States)

^v UNIVERSITY OF MANCHESTER   (United Kingdom)

^w SARAH CANNON RESEARCH INSTITUTE   (United States)

^x J and J Innovation   (United States)

^y GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; PLATINUM COMPLEX; RADIOSENSITIZING AGENT; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CONTROL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DNA DAMAGE; DRUG REPOSITIONING; HEAD AND NECK CANCER; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; IONIZING RADIATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; ORGANS AT RISK; OVERALL SURVIVAL; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; QUALITY OF LIFE; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; RADIOSENSITIZATION; STUDY DESIGN; TUMOR MICROENVIRONMENT; XEROSTOMIA; CELL HYPOXIA; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DRUG APPROVAL; HEALTH CARE QUALITY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATIENT EDUCATION; PROCEDURES; RADIATION DOSE; RADIATION RESPONSE; RADIATION TOLERANCE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG APPROVAL; HUMANS; NEOPLASMS; PATIENT EDUCATION AS TOPIC; PATIENT PARTICIPATION; QUALITY ASSURANCE, HEALTH CARE; QUALITY OF HEALTH CARE; RADIATION DOSAGE; RADIATION TOLERANCE; TREATMENT OUTCOME;

EID: 84973144148     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.79     Document Type: Article

References (156)

1. Stewart, B. W., & Wild, C. P. World Cancer Report (World Health Organisation Press, 2014
2. Department of Health. Radiotherapy in England. GOV.UK https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/213151/Radiotherapy-Services-in-England-2012.pdf (2012
3. Ringborg, U., et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001 - summary and conclusions. Acta Oncol. 42, 357-365 (2003
4. Lutz, S. T., Jones, J., & Chow, E. Role of radiation therapy in palliative care of the patient with cancer. J. Clin. Oncol. 32, 2913-2919 (2014
5. Cullen, J., Drabble, D., Castellanos, C., & Brissett, L. Recommendations for achieving a world-class radiotherapy service in the UK. The Tavistock Institute http://www.tavinstitute.org/wp-content/uploads/2014/05/Tavistock-Projects- Recommendations-for-achieving-a-world-class-radiotherapy-service-in-the-UK-.pdf (2014
6. Atun, R., et al. Expanding global access to radiotherapy. Lancet Oncol. 16, 1153-1186 (2015
7. Tree, A. C., et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 14, e28-e37 (2013
8. Chang, J. Y., Senan, S., Smit, E. F., & Roth, J. A. Surgery versus SABR for resectable non-small-cell lung cancer - authors? reply. Lancet Oncol. 16, e374-e375 (2015
9. Lawrence, Y. R., et al. NCIRTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J. Natl Cancer Inst. 105, 11-24 (2013
10. Ataman, O. U., et al. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective. Int. J. Radiat. Oncol. Biol. Phys. 84, e447-e454 (2012
11. Glass, C., Den, R. B., Dicker, A. P., & Lawrence, Y. R. Toxicity of phase I radiation oncology trials: worldwide experience. Int. J. Radiat. Oncol. Biol. Phys. 78, S65-S65 (2010
12. National Cancer Research Institute Clinical Studies Groups. Portfolio maps. NCRI Clinical Studies Groups http://csg.ncri.org.uk/portfolio/portfolio-maps/(2016
13. Niederhuber, J. E., Armitage, J. O., Doroshow, J. H., Kastan, M. B., & Tepper, J. E. Abeloff's Clinical Oncology (Elsevier Health Sciences, 2013
14. Haviland, J. S., et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10 year follow up results of two randomised controlled trials. Lancet Oncol. 14, 1086-1094 (2013
15. Dearnaley, D., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 13, 43-54 (2012
16. Lewanski, C. R., & Gullick, W. J. Radiotherapy and cellular signalling. Lancet Oncol. 2, 366-370 (2001
17. Nordsmark, M., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 77, 18-24 (2005
18. Kim, J. J., & Tannock, I. F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat. Rev. Cancer 5, 516-525 (2005
19. West, C. M., Davidson, S. E., Roberts, S. A., & Hunter, R. D. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br. J. Cancer 68, 819-823 (1993
20. Butterworth, K. T., McMahon, S. J., Hounsell, A. R., O'Sullivan, J. M., & Prise, K. M. Bystander signalling: exploring clinical relevance through new approaches and new models. Clin. Oncol. 25, 586-592 (2013
21. Marin, A., et al. Bystander effects and radiotherapy. Rep. Pract. Oncol. Radiother. 20, 12-21 (2015
22. Barcellos-Hoff, M. H., Park, C., & Wright, E. G. Radiation and the microenvironment - tumorigenesis and therapy. Nat. Rev. Cancer 5, 867-875 (2005
23. Demaria, S., Golden, E. B., & Formenti, S. C. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 1, 1325-1332 (2015
24. Illidge, T. Turning radiotherapy into an effective systemic anti-cancer treatment in combination with immunotherapy. Clin. Oncol. (R. Coll. Radiol.) 27, 696-699 (2015
25. Thompson, R. F., & Maity, A. Radiotherapy and the tumor microenvironment: mutual influence and clinical implications. Adv. Exp. Med. Biol. 772, 147-165 (2014
26. Yoshimura, M., Itasaka, S., Harada, H., & Hiraoka, M. Microenvironment and radiation therapy. Biomed. Res. Int. 2013, 685308 (2013
27. Shiao, S. L., & Coussens, L. M. The tumor-immune microenvironment and response to radiation therapy. J. Mammary Gland Biol. Neoplasia 15, 411-421 (2010
28. Dewan, M. Z., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA 4 antibody. Clin. Cancer Res. 15, 5379-5388 (2009
29. Golden, E. B., et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof of principle trial. Lancet Oncol. 16, 795-803 (2015
30. Hingorani, M., et al. Combining radiation and cancer gene therapy: a potential marriage of physical and biological targeting?. Curr. Cancer Drug Targets 7, 389-409 (2007
31. Mengesha, A., et al. Potential and limitations of bacterial-mediated cancer therapy. Front. Biosci. 12, 3880-3891 (2007
32. Harrington, K. J., et al. Phase I/II study of oncolytic HSV GM CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 16, 4005-4015 (2010
33. Barker, H. E., Paget, J. T., Khan, A. A., & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409-425 (2015
34. European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man. European Medicines Agency http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2013/01/WC500137128.pdf (2012
35. U.S. Food and Drug Administration. Guidance for industry: codevelopment of two or more new investigational drugs for use in combination. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm236669.pdf (2013
36. Cook, D., et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419-431 (2014
37. Medicines and Healthcare Products Regulatory Agency. Marketing authorisations, variations and licensing guidance. GOV.UK https://www.gov.uk/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing (2016
38. European Medicines Agency. Priority medicines (PRIME) scheme. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general- content-000660.jsp& mid= (2015
39. Hill, E. J., et al. Clinical trial of oral nelfinavir before and during radiation therapy for advanced rectal cancer. Clin. Cancer Res. 22, 1922-1931 (2016
40. U.S. Food and Drug Administration. Frequently asked questions on patents and exclusivity. http://www.fda.gov/Drugs/DevelopmentApproval Process/ucm079031.htm (2014
41. European Medicines Agency. Data exclusivity, market protection and paediatric rewards. http://www.ema. europa.eu/docs/en-GB/document-library/Presentation/2013/05/WC500143122.pdf (2013
42. Maas, M., et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 11, 835-844 (2010
43. Le Scodan, R., et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J. Clin. Oncol. 27, 1375-1381 (2009
44. Emami, B., et al. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 21, 109-122 (1991
45. Bentzen, S. M., et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int. J. Radiat. Oncol. Biol. Phys. 76, S3-S9 (2010
46. Bentzen, S. M., et al. Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int. J. Radiat. Oncol. Biol. Phys. 76, S145-S150 (2010
47. Harrington, K. J., et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br. J. Cancer 105, 628-639 (2011
48. Seiwert, T. Y., Salama, J. K., & Vokes, E. E. The concurrent chemoradiation paradigm - general principles. Nat. Clin. Pract. Oncol. 4, 86-100 (2007
49. Di Maio, M., Basch, E., Bryce, J., & Perrone, F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat. Rev. Clin. Oncol. 13, 319-325 (2016
50. Ang, K. K., et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol. 32, 2940-2950 (2014
51. National Cancer Institute. NCI Dictionary of Cancer Terms. http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=546597 (2016
52. Glynne-Jones, R., Dunst, J., & Sebag-Montefiore, D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?. Ann. Oncol. 17, 361-371 (2006
53. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446 (2010
54. Tallarida, R. J. Quantitative methods for assessing drug synergism. Genes Cancer 2, 1003-1008 (2011
55. Jain, R. K., et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin. Cancer Res. 16, 1289-1297 (2010
56. O'Connor, J. P., Jackson, A., Parker, G. J., Roberts, C., & Jayson, G. C. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat. Rev. Clin. Oncol. 9, 167-177 (2012
57. Smethurst, D., & Hughes, A. A. Proposed structure to classify levels of proof within a clinical development programme. Int. J. Pharm. Med. 19, 227-232 (2005
58. Pijls-Johannesma, M., et al. A systematic methodology review of phase I radiation dose escalation trials. Radiother. Oncol. 95, 135-141 (2010
59. Cheung, Y. K., & Chappell, R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56, 1177-1182 (2000
60. Desai, S. P., et al. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J. Clin. Oncol. 25, 4587-4592 (2007
61. Le Tourneau, C., Lee, J. J., & Siu, L. L. Dose escalation methods in phase I cancer clinical trials. J. Natl Cancer Inst. 101, 708-720 (2009
62. Thall, P. F., & Cook, J. D. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60, 684-693 (2004
63. Van Baardwijk, A., et al. Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. Eur. J. Cancer 48, 2339-2346 (2012
64. De Ruysscher, D., et al. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study. Radiother. Oncol. 102, 228-233 (2012
65. Christodoulou, M., Bayman, N., McCloskey, P., Rowbottom, C., & Faivre-Finn, C. New radiotherapy approaches in locally advanced non-small cell lung cancer. Eur. J. Cancer 50, 525-534 (2014
66. Zindler, J. D., et al. Increasing the therapeutic ratio of stereotactic ablative radiotherapy by individualized isotoxic dose prescription. J. Natl Cancer Inst. 108, djv305 (2015
67. Mander, A. P., & Sweeting, M. J. A product of independent beta probabilities dose escalation design for dual-agent phase I trials. Stat. Med. 34, 1261-1276 (2015
68. Redig, A. J., & Janne, P. A. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J. Clin. Oncol. 33, 975-977 (2015
69. Freidlin, B., McShane, L. M., Polley, M. Y., & Korn, E. L. Randomized phase II trial designs with biomarkers. J. Clin. Oncol. 30, 3304-3309 (2012
70. McShane, L. M., Hunsberger, S., & Adjei, A. A. Effective incorporation of biomarkers into phase II trials. Clin. Cancer Res. 15, 1898-1905 (2009
71. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001
72. Yap, T. A., Sandhu, S. K., Workman, P., & De Bono, J. S. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 10, 514-523 (2010
73. Mehta, S., et al. Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. J. Natl Cancer Inst. Monogr. 2011, 71-74 (2011
74. Peeters, S. G., et al. TH 302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging. Clin. Cancer Res. 21, 2984-2992 (2015
75. Tournoux, C., De Rycke, Y., Medioni, J., & Asselain, B. Methods of joint evaluation of efficacy and toxicity in phase II clinical trials. Contemp. Clin. Trials 28, 514-524 (2007
76. Taichman, D. B., et al. Sharing clinical trial data - a proposal from the International Committee of Medical Journal Editors. N. Engl. J. Med. 374, 384-386 (2016
77. Peters, L. J., et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J. Clin. Oncol. 28, 2996-3001 (2010
78. Melidis, C., et al. Radiation therapy quality assurance in clinical trials - Global Harmonisation Group. Radiother. Oncol. 111, 327-329 (2014
79. Hidalgo, M., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998-1013 (2014
80. Sharpless, N. E., & Depinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5, 741-754 (2006
81. Verhaegen, F., Granton, P., & Tryggestad, E. Small animal radiotherapy research platforms. Phys. Med. Biol. 56, R55-R83 (2011
82. Verhaegen, F., Van Hoof, S., Granton, P. V., & Trani, D. A review of treatment planning for precision image-guided photon beam pre-clinical animal radiation studies. Z. Med. Phys. 24, 323-334 (2014
83. Baumann, M., et al. Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse. Int. J. Radiat. Biol. 79, 547-559 (2003
84. Bonner, J. A., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006
85. Krause, M., et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother. Oncol. 74, 109-115 (2005
86. Denekamp, J., Ball, M. M., & Fowler, J. F. Recovery and repopulation in mouse skin as a function of time after x irradiation. Radiat. Res. 37, 361-370 (1969
87. Rojas, A., et al. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x ray schedules. Radiother. Oncol. 39, 53-64 (1996
88. Stewart, F. A., Denekamp, J., & Randhawa, V. S. Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia. Br. J. Cancer 45, 869-877 (1982
89. Douglas, B. G., & Fowler, J. F. The effect of multiple small doses of x rays on skin reactions in the mouse and a basic interpretation. Radiat. Res. 66, 401-426 (1976
90. Dorr, W., & Hendry, J. H. Consequential late effects in normal tissues. Radiother. Oncol. 61, 223-231 (2001
91. Denekamp, J. Early and late radiation reactions in mouse feet. Br. J. Cancer 36, 322-329 (1977
92. Citrin, D. E., et al. Role of type II pneumocyte senescence in radiation-induced lung fibrosis. J. Natl Cancer Inst. 105, 1474-1484 (2013
93. Moore, B. B., & Hogaboam, C. M. Murine models of pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L152-L160 (2008
94. Giridhar, P., Mallick, S., Rath, G. K., & Julka, P. K. Radiation induced lung injury: prediction, assessment and management. Asian Pac. J. Cancer Prev. 16, 2613-2617 (2015
95. Ding, N. H., Li, J. J., & Sun, L. Q. Molecular mechanisms and treatment of radiation-induced lung fibrosis. Curr. Drug Targets 14, 1347-1356 (2013
96. Tung, D., et al. Differential effects of cyclosporin and etanercept treatment on various pathologic parameters in a murine model of irradiation-induced mucositis. Curr. Ther. Res. Clin. Exp. 73, 150-164 (2012
97. Qayum, N., et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res. 69, 6347-6354 (2009
98. Vergis, R., et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 9, 342-351 (2008
99. Lalonde, E., et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5 year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 15, 1521-1532 (2014
100. Palmer, G. M., Fontanella, A. N., Shan, S., & Dewhirst, M. W. High-Resolution In Vivo Imaging of Fluorescent Proteins Using Window Chamber Models (Humana Press, 2012
101. National Cancer Research Institute Consumer Forum. Consumer report Pro-forma. http://www.ncri.org.uk/wp-content/uploads/2016/02/CSG-Consumer-Report-September-2015.pdf (2015
102. Ozdemir, B. A., et al. Research activity and the association with mortality. PLoS ONE 10, e0118253 (2015
103. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987-989 (2001
104. Nieder, C., Pawinski, A., Dalhaug, A., & Andratschke, N. A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. Radiat. Oncol. 7, 3 (2012
105. Maier, P., Wenz, F., & Herskind, C. Radioprotection of normal tissue cells. Strahlenther. Onkol. 190, 745-752 (2014
106. Postow, M. A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931 (2012
107. Vatner, R. E., Cooper, B. T., Vanpouille-Box, C., Demaria, S., & Formenti, S. C. Combinations of immunotherapy and radiation in cancer therapy. Front. Oncol. 4, 325 (2014
108. Stupp, R., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009
109. Fojo, T., & Grady, C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101, 1044-1048 (2009
110. Brown, B., et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 11, 791-799 (2008
111. Tsang, Y., Haviland, J., Venables, K., & Yarnold, J. The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiother. Oncol. 104, 143-147 (2012
112. Ippolito, E., et al. Early proctoscopy is a surrogate endpoint of late rectal toxicity in prostate cancer treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 83, e191-e195 (2012
113. Boothe, D. L., et al. Transforming growth factor β 1 (TGF β1) is a serum biomarker of radiation induced fibrosis in patients treated with intracavitary accelerated partial breast irradiation: preliminary results of a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 87, 1030-1036 (2013
114. He, J., et al. The association between TGF β1 polymorphisms and radiation pneumonia in lung cancer patients treated with definitive radiotherapy: a meta-analysis. PLoS ONE 9, e91100 (2014
115. Postel-Vinay, S., et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?. J. Clin. Oncol. 29, 1728-1735 (2011
116. Hanna, N., et al. Holland-Frei Cancer Medicine 6th edn (2003
117. Fornander, T., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1, 117-120 (1989
118. Bresalier, R. S., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005
119. Ewer, M. S., & Lippman, S. M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol. 23, 2900-2902 (2005
120. US National Library of Science. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02264678 (2016
121. Bentzen, S. M. Radiobiological considerations in the design of clinical trials. Radiother. Oncol. 32, 1-11 (1994
122. Diez, P., Vogelius, I. S., & Bentzen, S. M. A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 77, 1066-1071 (2010
123. Good, J. S., & Harrington, K. J. The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. Clin. Oncol. (R. Coll. Radiol) 25, 569-577 (2013
124. Hudis, C. A., et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J. Clin. Oncol. 25, 2127-2132 (2007
125. Hanna, T. P., Shafiq, J., Delaney, G. P., & Barton, M. B. The population benefit of radiotherapy for cervical cancer: local control and survival estimates for optimally utilized radiotherapy and chemoradiation. Radiother. Oncol. 114, 389-394 (2015
126. Mayr, N. A., et al. Longitudinal changes in tumor perfusion pattern during the radiation therapy course and its clinical impact in cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 77, 502-508 (2010
127. Gadducci, A., et al. Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach. Anticancer Res. 30, 3731-3735 (2010
128. Rouzier, R., et al. Survival in cervix cancer patients treated with radiotherapy followed by radical surgery. Eur. J. Surg. Oncol. 31, 424-433 (2005
129. Kawaguchi, R., Furukawa, N., Kobayashi, H., & Asakawa, I. Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy. J. Gynecol. Oncol. 24, 313-320 (2013
130. D'Amico, A. V., et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol. 13, 189-195 (2012
131. Ray, M. E., et al. Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J. Natl Cancer Inst. 101, 228-236 (2009
132. Machtay, M., et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J. Thorac. Oncol.7 716-722 (2012
133. Mauguen, A., et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re analysis of meta-analyses of individual patients? data. Lancet Oncol. 14, 619-626 (2013
134. Machtay, M., et al. Prediction of survival by [18F] fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J. Clin. Oncol. 31, 3823-3830 (2013
135. Hiltermann, T. J., et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann. Oncol. 23, 2937-2942 (2012
136. Milosevic, M., et al. Radiotherapy for bladder cancer. Urology 69, 80-92 (2007
137. Feuerstein, M. A., & Goenka, A. Quality of life outcomes for bladder cancer patients undergoing bladder preservation with radiotherapy. Curr. Urol. Rep. 16, 75 (2015
138. Rfdel, C., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J. Clin. Oncol. 20, 3061-3071 (2002
139. Huddart, R. A., et al. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int. J. Radiat. Oncol. Biol. Phys. 87, 261-269 (2013
140. Sjoquist, K. M., et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12, 681-692 (2011
141. Berger, A. C., et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J. Clin. Oncol. 23, 4330-4337 (2005
142. Swisher, S. G., et al. 2 Fluoro-2 deoxy D glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101, 1776-1785 (2004
143. Patel, U. B., et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J. Clin. Oncol. 29, 3753-3760 (2011
144. Glynne-Jones, R., Adams, R. A., Jitlal, M., & Meadows, H. End points in anal cancer: hopes for a common language. J. Clin. Oncol. 32, 1281-1282 (2014
145. Day, F. L., et al. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Br. J. Cancer 105, 498-504 (2011
146. Schwarz, J. K., et al. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int. J. Radiat. Oncol. Biol. Phys. 71, 180-186 (2008
147. Deniaud-Alexandre, E., et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int. J. Radiat. Oncol. Biol. Phys. 56, 1259-1273 (2003
148. Tzeng, C. W., et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford) 16, 430-438 (2014
149. Rudra, S., et al. Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Pract. Radiat. Oncol. 2, 77-85 (2012
150. Amin, A., et al. Pentavalent Technetium 99m Dimercaptosuccinic Acid [Tc 99m (V) DMSA] Brain SPECT: Does It Have A Place in Predicting Survival in Patients with Glioblastoma Multiforme?. J. Neurooncol. 121, 303-309 (2015
151. Shah, G. D., et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 8, 38-46 (2006
152. Chen, Y. P., et al. Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial. Sci. Rep. 5, 12502 (2015
153. Michiels, S., et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 10, 341-350 (2009
154. Xie, P., et al. 18F FDG PET or PET CT to evaluate prognosis for head and neck cancer: a meta-analysis. J. Cancer Res. Clin. Oncol. 137, 1085-1093 (2011
155. Hentschel, M., et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur. J. Nucl. Med. Mol. Imaging 38, 1203-1211 (2011
156. Cortazar, P., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164-172 (2014